Clinically, PGM3 deficient patients are marked with a group of immunologic and neurologic impairments. Often patients present with similar manifestations to
Hyperimmunoglobulin E syndrome (HIES), including severe
atopic dermatitis, chronic
sinusitis or otitis,
cutaneous vasculitis, severe pulmonary infections and
pneumonia, and very high concentrations of the serum antibody
IgE levels. Skin infections are prominent, with recurrent
staphylococcal and fungal infections, severe skin blistering, and
flat warts. Patients are susceptible to reoccurring pulmonary infections that may lead to
bronchiectasis in the future. Additionally,
scoliosis and
microcephaly have also been identified. In addition to severe
immunodeficiency, motor and neurologic impairment are evident from early life. Oral motor deficits,
dysarthria, developmental delay,
ataxia,
myoclonus, seizure and mild sensory loss have all been identified. These distinctive neurologic features are suggestive of hypomyelination, as they resemble features of other
congenital disorder of glycosylation (CDGs). Because glycosylation is known to be critical for numerous immune-related proteins, these patients likely present with additional abnormalities including hemolytic
anemia,
hepatosplenomegaly, and
neutropenia. An immunologic mechanism to explain the link between glycosylation abnormalities and the immune dysregulation has not yet been established. This disorder demonstrates a previously unappreciated importance that glycosylation can have on the immune response and more research is needed to examine the precise mechanism by which these mutations and abnormal glycosylation lead to the clinical defects observed ==Genetics ==